Drugs
A phase II study examining the effectiveness of the irinotecan and docetaxel therapy in pre-treated metastatic breast cancer patients has shown promising results. The study, conducted by G.P. Stathopoulos and colleagues at the Errikos Dunant Hospital, involved 48 patients, all of whom had been previously treated with anthracycline-combined chemotherapy.
Drugs
Researchers at the University of Queensland's Centre for Immunology and Cancer Research (CICR) have made a significant breakthrough in the treatment of cervical cancer. Using a novel technique called "gene silencing", scientists have been able to target and eliminate the formation of cancer tumors in animal
Drugs
Introgen Therapeutics, Inc. (INGN) has unveiled data on a novel mechanism of action for its therapy, INGN 241, which targets the formation of new blood vessels in tumors, a process called angiogenesis. This mechanism is crucial for tumors to establish a sufficient supply of oxygen and nutrients, leading to tumor
Drugs
Researchers presented clinical data at the Chemotherapy Foundation Symposium XXIII on Abraxane, a chemotherapy treatment that targets difficult-to-treat tumors. The studies showed high response rates in various types of cancer, including non-small cell lung cancer, metastatic malignant melanoma, and head and neck cancer. The treatment works by exploiting a protein
Drugs
Researchers in Italy, Canada, and the United States have made significant progress in cancer therapy research, exploring innovative approaches to treat metastatic breast cancer, prostate cancer, and breast cancer. Studies suggest that metronomic therapy, modified metronomic combination therapy, and cyclooxygenase-2 (COX-2) inhibitors show promise in reducing healthcare costs, improving efficacy,
Drugs
BioWa, Inc. has secured worldwide rights, excluding Asia, to develop and commercialize a monoclonal antibody targeting fibroblast growth factor 8 (FGF8), a potential new treatment for breast, ovarian, and prostate cancers. This agreement grants Kyowa Hakko Kogyo Co., Ltd., BioWa's parent company, an option to develop and commercialize
Drugs
Celera Genomics, an Applera Corporation business, has made significant progress in its histone deacetylase (HDAC) inhibitor program, presenting three posters at the American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics meeting. The company's scientists reported extensive molecular profiling of CRA-024781, a potent HDAC
Drugs
Researchers led by Intae Lee, PhD, Department of Radiology, University of Pennsylvania, have presented new data on the effectiveness of Onconase (ranpirnase) against non-small cell lung cancer (NSCLC) at the 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO). The study, titled "The Enhanced Efficacy
Drugs
Researchers at the University of Texas M.D. Anderson Cancer Center have found that curcumin, the main ingredient of turmeric, inhibits metastasis to the lungs of mice with breast cancer. The study, published in the journal Clinical Cancer Research, reports that curcumin appears to shut down a protein active in
Drugs
Viventia Biotech Inc. has received clearance from Health Canada to initiate a phase 2 study evaluating Proxinium for the treatment of patients with chemotherapy-refractory recurrent head and neck cancer. Following the FDA's clearance in October 2005, the company is set to initiate the trial by the end of
Drugs
Dr. Bernard Escudier, Head of Immunotherapy and Innovative Therapy Unit at the Gustave-Roussy Institute in Paris, presented interim results from the Phase III trial of Nexavar in patients with advanced renal cell carcinoma (RCC) at the 13th European Cancer Conference (ECCO). The study showed a significant improvement in survival for
Drugs
Researchers in the United States, South Korea, and Netherlands have made significant strides in cancer therapy research, with breakthroughs in the treatment of various types of cancer, including nasopharyngeal carcinoma, hepatocellular carcinoma, and colorectal cancer. Recent studies have focused on the development of new agents and therapies that target specific
